S

Sanofi

Global pharma company; vaccines and R&D

Global Category Manager for Digital

Full-TimeUpdated on 10/23/2026Deadline 10/28/26
€69.2k - €103.8k
Expert
Master's
Barcelona, Spain
In Person
Operations & LogisticsProcurement & Sourcing

About the job

Requirements
  • At least 15 years of experience in procurement or a closely related field, with proven global-scale expertise in digital/IT category management covering software, IT services, and hardware.
  • Mastery of procurement methodologies, including total cost of ownership, supplier relationship management, market intelligence, and risk management.
  • Strong negotiation skills in complex global contracts.
  • A strategic, results-driven, and analytical mindset.
  • Ability to engage C-suite stakeholders confidently.
  • Strong influencing skills across diverse, multicultural teams.
  • Understanding of business, legal, and operational dimensions, including service-level agreements and key performance indicators.
  • Experience navigating complex matrix organizations.
  • High ethical standards and commitment to business integrity.
  • A Master's degree from an accredited college or university.
  • Fluency in English.
Responsibilities
  • Own end-to-end category strategy for software, IT services, and strategic hardware across all Sanofi entities worldwide.
  • Design and execute competitive category strategies based on market intelligence, risk assessment, and long-range business planning.
  • Develop supplier market expertise and identify emerging technologies, new suppliers, and service models.
  • Contribute to the AI-powered procurement transformation.
  • Build and maintain a sub-category roadmap with a project and savings pipeline aligned to budget cycles.
  • Deliver year-over-year savings targets and optimize Business Operational Impact.
  • Lead strategic negotiations, globalization programs, harmonization initiatives, and critical supplier escalations.
  • Establish risk mitigation plans supported by supplier assessments and scorecards.
  • Engage senior leaders across Global Business Units and Support Functions to align procurement strategies with business needs.
  • Partner with Country Procurement Heads to translate global strategies at the local level.
  • Share market trends, benchmarks, and budget assumptions with stakeholders.
  • Coach and develop Global Lead Buyers and domain team members.
  • Foster a culture of procurement excellence, ethics, and continuous improvement.
Desired Qualifications
  • Additional languages are a plus.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...